Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving Average – What’s Next?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) shares crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $3.36 and traded as high as $3.40. Voyager Therapeutics shares last traded at $3.32, with a volume of 716,940 shares.

Analysts Set New Price Targets

A number of brokerages recently commented on VYGR. Weiss Ratings restated a “sell (d-)” rating on shares of Voyager Therapeutics in a report on Monday, July 13th. Wall Street Zen lowered shares of Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, HC Wainwright reissued a “buy” rating on shares of Voyager Therapeutics in a research report on Monday, August 10th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Voyager Therapeutics Stock Down 2.6%

The stock has a market capitalization of $204.57 million, a PE ratio of -1.84 and a beta of 1.31. The stock has a fifty day moving average of $3.36 and a 200-day moving average of $3.69.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.08. The company had revenue of $3.17 million for the quarter, compared to the consensus estimate of $4.52 million. Voyager Therapeutics had a negative return on equity of 57.92% and a negative net margin of 312.63%. Equities research analysts expect that Voyager Therapeutics, Inc. will post -1.63 EPS for the current year.

Institutional Trading of Voyager Therapeutics

A number of large investors have recently made changes to their positions in VYGR. AQR Capital Management LLC lifted its stake in Voyager Therapeutics by 179.3% in the first quarter. AQR Capital Management LLC now owns 495,260 shares of the company’s stock worth $1,674,000 after acquiring an additional 317,927 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Voyager Therapeutics during the 1st quarter worth approximately $218,000. Acadian Asset Management LLC increased its position in shares of Voyager Therapeutics by 863.3% in the 1st quarter. Acadian Asset Management LLC now owns 230,708 shares of the company’s stock valued at $778,000 after purchasing an additional 206,758 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Voyager Therapeutics by 1.1% in the 2nd quarter. Geode Capital Management LLC now owns 1,116,847 shares of the company’s stock valued at $3,474,000 after purchasing an additional 11,929 shares during the last quarter. Finally, American Century Companies Inc. raised its holdings in shares of Voyager Therapeutics by 5.1% in the 2nd quarter. American Century Companies Inc. now owns 138,269 shares of the company’s stock valued at $430,000 after purchasing an additional 6,748 shares in the last quarter. 48.03% of the stock is currently owned by hedge funds and other institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of gene therapies for serious neurological diseases. The company’s core activities center on the design and delivery of engineered adeno-associated viral (AAV) vectors tailored to target cells in the brain and central nervous system. Through its proprietary CapsidMap and VectorMap platforms, Voyager aims to enhance vector potency, specificity and durability to address diseases with high unmet medical need.

The firm’s pipeline includes several AAV-based candidates in preclinical and early clinical development.